This study is for adults with advanced solid tumors, a type of cancer, that have a specific change in their KRAS gene called **G12C mutation**. The study tests a new drug, **JDQ443**, alone or with other treatments (**TNO155** and **tislelizumab**), to see how safe it is and if it works. This is a **phase Ib/II open label study**, meaning that researchers and participants know what treatment is given, and it's early in testing these treatments for safety and effectiveness. The study will first find the safest dose, then see how well it works to stop tumor growth.
**Key Points:**
- Participants must be adults with advanced KRAS G12C mutant tumors, not responding to standard treatments.
- Some previous treatments are allowed, and there may be multiple study visits.
- There are certain health conditions that would prevent joining, like significant heart issues or specific brain problems.
How understandable was the trial content above?
Hard to understand
Easy to understand